HomeProductsBioactive CompoundsImmunology & InflammationTLRMotolimod
Chemical structure of CAS 926927-61-9

Motolimod

CAS No.926927-61-9
MDL No.MFCD28044318
MFC28H34N4O2
MW458.60
InChI KeyQSPOQCXMGPDIHI-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.926927-61-9
Product NameMotolimod

Biological Targets

TLR8

Associated Conditions

verrucous carcinoma·squamous cell carcinoma·oropharyngeal carcinoma·ovarian cancer·tongue cancer·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

The IUPHAR Guide to Immunopharmacology: connecting immunology and pharmacology.

Immunology • Vol. 160, Issue 1 • 2020
PMID: 32020584PMC: PMC7160657DOI: 10.1111/imm.13175

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 23, Issue 10 • 2017
PMID: 27810904DOI: 10.1158/1078-0432.CCR-16-1934

Motolimod effectively drives immune activation in advanced cancer patients.

Oncoimmunology • Vol. 5, Issue 5 • 2016
PMID: 27467937PMC: PMC4910739DOI: 10.1080/2162402X.2015.1126037

VTX-2337 is a novel TLR8 agonist that activates NK cells and augments ADCC.

Clinical cancer research : an official journal of the American Association for Cancer Research • Vol. 18, Issue 2 • 2012
PMID: 22128302DOI: 10.1158/1078-0432.CCR-11-1625

Documentation